⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 18, 2024Antimicrobial Agents and Chemotherapy

The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-β-lactamase against tebipenem

Daisuke Ono Anna Cmolik Christopher R. Bethel Yoshikazu Ishii Salvador I. Drusin Diego M. Moreno Alejandro J. Vila Robert A. Bonomo María F. Mojica

View at Publisher

Ask AI

Bookmark

Share

Abstract

Imipenemase (IMP) metallo-β-lactamases (MBLs) hydrolyze almost all available β-lactams including carbapenems and are not inhibited by any commercially available β-lactamase inhibitor. Tebipenem (TP) pivoxil is the first orally available carbapenem and possesses a unique bicyclic azetidine thiazole moiety located at the R2 position. TP has potent

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ono et al. (2024) studied this question.

synapsesocial.com/papers/68e5fda8b6db6435875912da https://doi.org/10.1128/aac.00687-24

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Chelate-conjugated β-lactams resensitize metallo-β-lactamase IMP-1-producing gram-negative bacteria against carbapenem antibioticsOriginal Research · 2026
2Tebipenem pivoxil hydrobromide—No PICC, no problem!Late-Phase Clinical Trial · 2021 · 16 citations
3<i>In Vitro</i> and <i>In Vivo</i> Characterization of Tebipenem, an Orally Active Carbapenem, against Biothreat PathogensOriginal Research · 2021 · 13 citations
4P-1213. Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023Original Research · 2026
5Resistance of Uropathogens to Tebipenem: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility StudiesReview · 2026 · 1 citations

More related papers

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance2026
P-1214. In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-20242026
Targeting Metallo-β-Lactamases:Discovery ofNovel Dihydro-Chromeno Pyrrole (dCPs) Derivatives for Combating Drug-ResistantInfections2026

More from Antimicrobial Agents and Chemotherapy

Activity of oral β-lactams, tebipenem and ceftibuten, combined with novel oral β-lactamase inhibitors against broad-spectrum β-lactamase-producing Escherichia coliWed,
Rifampicin-resistant Staphylococcus epidermidis implant-associated infections: the therapeutic potential of ceftaroline and daptomycin combinationsWed,